I read with interest the comments of Profes sors Hughes and Hartung regarding the use of plasmapheresis to treat neurological dis orders based on the most recent American Academy of Neurology (AAN) practice guideline (Neuroimmunology: Assessing the value of plasma exchange in neurology. Nat. Rev. Neurol. 7, 309-310; 2011) .
1 I was disappointed to see that the authors did not cite our class II study, 2 refer enced in the AAN practice guideline, 3 which provides strong support for the use of plasma exchange to treat acute, severe relapses of inflammatory demyelinating disease that are refractory to standard treatment with corticosteroids.
Our study was a randomized, double blind, shamcontrolled evaluation of 22 patients with severe corticosteroid refractory attacks of inflammatory demye linating disease. 2 The study design included a crossover, allowing both intrapatient and interpatient comparisons of response to active and sham plasmapheresis treat ment. The outcomes required to declare success in this study were moderate to marked improvements in neurological defi cits. Largely on the basis of this study, the Therapeutics and Technology Assessment Subcommittee of the AAN reached the fol lowing recommendation: "plasmapheresis may be considered in the treatment of ful minant CNS demyelinating diseases that fail to respond to highdose corticosteroid treatment (Level C)." 3 The main concerns that limited a higher rating of the evidence were the small size of the study and the heterogeneity of the inflammatory demye linating diseases that were included in the study. Inflammatory demyelinating diseases are notoriously difficult to accurately clas sify at initial presentation. 4 For example, acute transverse myelitis may occur as a nonrecurring entity or as part of acute disseminated encephalomyelitis or, on the basis of further followup, may be reclassi fied as an initial attack of multiple sclerosis or neuromyelitis optica.
One of the key messages of our study 2 is that the exact classification of demyelinating Plasmapheresis: are bigger studies necessarily better?
Brian Weinshenker syndrome does not matter greatly in terms of acute treatment of an attack: favourable responses occurred throughout the steroid refractory CNS inflammatory diseases that we evaluated. Subsequent retrospective analyses have similarly supported the use of plasma exchange in a variety of demye linating syndromes, 5-9 as have prospective uncontrolled studies in diverse CNS demye linating diseases. [10] [11] [12] As noted by Hughes and Hartung, attacks of inflammatory demye linating disease improve spontaneously, confounding the reliability of studies that target a broader population of these patients. Our study 2 was a focused study concentrat ing on the subgroup of patients who failed to respond to steroids, the subgroup of greatest concern to clinicians treating these diseases. Although failure to recover from an attack of demyelinating disease is an uncommon situ ation, it is certainly one that occurs with suffi cient frequency to create a substantial clinical challenge to clinicians caring for patients with these conditions. It is a particularly common challenge in severe inflammatory demyelinat ing diseases such as neuromyelitis optica that our group has been able to define. 13 Large positive studies that include all patients with relapses of inflammatory demyelinat ing disease would certainly provide robust support for plasmapheresis in this setting and would impress Cochrane reviewers.
We agree that small subgroup studies such as ours should be confirmed by further studies. We also believe that it is a mistake to ignore small, effectively blinded and well focused studies performed in a subgroup of patients, especially when targeting serious acute illnesses with major neurological defi cits. We do not believe, however, that large randomized studies are required in such patient subgroups before the results are acceptable to guide everyday practice. Focus ing only on the equivocal results of large studies in unselected and fundamen tally uninformative groups of patients with limited power may prevent the appropriate patients from receiving beneficial treatments that significantly reduce morbidity.
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